• NewAmsterdam Pharma and Menarini Group previously announced that the EMA’s CHMP issued a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) in European patients with primary hypercholesterolemia and mixed dyslipidemia.
• This opinion, backed by extensive Phase 2 and Phase 3 data showing meaningful LDL-C reductions with placebo-like tolerability, could reshape NewAmsterdam’s commercial outlook through Menarini’s exclusive European rights and a royalties-and-milestones structure worth up to €833 million.
• Against the backdrop of a recent 7-day share price decline, we’ll explore how the CHMP’s positive opinion influences NewAmsterdam Pharma’s investment narrative.

The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is NewAmsterdam Pharma's Investment Narrative?

To own NewAmsterdam Pharma, you really have to believe obicetrapib can transition from a well‑tolerated LDL‑lowering drug in trials into a meaningful commercial franchise, while the company manages ongoing losses and execution risk. The CHMP’s positive opinion on Ubeslo and Evlarco is an important step because it brings NewAmsterdam closer to royalty and milestone cash flows from Menarini, even as the share price has pulled back over the past month. In the near term, the key catalysts still look like the European Commission decision and progress updates on the PREVAIL outcomes trial, but the CHMP news may ease some regulatory uncertainty around the core lipid‑lowering story. At the same time, leadership turnover and continued cash burn remain front‑of‑mind risks.

However, one operational risk in particular is worth investors paying close attention to. Despite retreating, NewAmsterdam Pharma's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span from about US$51 to a very large figure, showing how far apart private investors can be. Set that against the current focus on regulatory decisions and ongoing cash burn, and you can see why it pays to understand several different viewpoints before forming your own.

Explore 3 other fair value estimates on NewAmsterdam Pharma - why the stock might be a potential multi-bagger!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free NewAmsterdam Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.